Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Head and Neck Cancer

  Free Subscription


Articles published in Br J Ophthalmol

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    January 2021
  1. SINGH L, Singh MK, Rizvi MA, Pushker N, et al
    Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Br J Ophthalmol. 2021;105:48-56.
    PubMed     Abstract available


    April 2020
  2. KWON M, Lee JS, Lee C, Yoon DH, et al
    Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification.
    Br J Ophthalmol. 2020 Apr 23. pii: bjophthalmol-2020-315875.
    PubMed     Abstract available


    July 2019
  3. WANG L, Ding L, Liu Z, Sun L, et al
    Automated identification of malignancy in whole-slide pathological images: identification of eyelid malignant melanoma in gigapixel pathological slides using deep learning.
    Br J Ophthalmol. 2019 Jul 13. pii: bjophthalmol-2018-313706.
    PubMed     Abstract available


  4. MCGRATH LA, Meeney A, Currie ZI, Mudhar HS, et al
    Staged excision of primary periocular basal cell carcinoma: absence of residual tumour in re-excised specimens: a 10-year series.
    Br J Ophthalmol. 2019;103:976-979.
    PubMed     Abstract available


    April 2019
  5. BHARDWAJ M, Sen S, Chosdol K, Bakhshi S, et al
    Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma.
    Br J Ophthalmol. 2019 Apr 2. pii: bjophthalmol-2018-313285.
    PubMed     Abstract available


    August 2018
  6. SA HS, Rubin ML, Xu S, Ning J, et al
    Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients.
    Br J Ophthalmol. 2018 Aug 21. pii: bjophthalmol-2018-312635.
    PubMed     Abstract available


    July 2018
  7. SAGIV O, Nagarajan P, Ferrarotto R, Kandl TJ, et al
    Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
    Br J Ophthalmol. 2018 Jul 18. pii: bjophthalmol-2018-312277.
    PubMed     Abstract available


    April 2018
  8. LEE GI, Kim YD, Young SM, Shin S, et al
    Clinical characteristics and treatment outcomes of natural killer/T-cell lymphoma involving the ocular adnexa.
    Br J Ophthalmol. 2018 Apr 29. pii: bjophthalmol-2017-311704.
    PubMed     Abstract available


    February 2018
  9. JAYARAJ P, Sen S, Rangarajan S, Ray N, et al
    Immunohistochemical evaluation of stress-responsive protein sestrin2 and its correlation with p53 mutational status in eyelid sebaceous gland carcinoma.
    Br J Ophthalmol. 2018 Feb 24. pii: bjophthalmol-2017-311283.
    PubMed     Abstract available


  10. LAM SC, Li EYM, Yuen HKL
    14-year case series of eyelid sebaceous gland carcinoma in Chinese patients and review of management.
    Br J Ophthalmol. 2018 Feb 19. pii: bjophthalmol-2017-311533.
    PubMed     Abstract available


    January 2018
  11. WAWRZYNSKI J, Tudge I, Fitzgerald E, Collin R, et al
    Report on the incidence of squamous cell carcinomas affecting the eyelids in England over a 15-year period (2000-2014).
    Br J Ophthalmol. 2018 Jan 23. pii: bjophthalmol-2017-310956.
    PubMed     Abstract available


    February 2017
  12. SALEH GM, Desai P, Collin JR, Ives A, et al
    Incidence of eyelid basal cell carcinoma in England: 2000-2010.
    Br J Ophthalmol. 2017;101:209-212.
    PubMed     Abstract available


    January 2017
  13. BHARDWAJ M, Sen S, Chosdol K, Sharma A, et al
    miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma.
    Br J Ophthalmol. 2017 Jan 24. pii: bjophthalmol-2016-309460.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: